New hope for rare liver disease: long-term drug trial targets severe itching
Disease control
Recruiting now
This study looks at the long-term safety and effectiveness of odevixibat in people with Alagille syndrome, a rare genetic disorder that affects the liver and other organs. The drug is already approved in the US to treat severe itching caused by bile buildup. Researchers will trac…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated May 14, 2026 12:04 UTC